Article Sidebar

PDF
Date Published: 16/05/2023
Abstract Views: 207
Views PDF: 102
DOI: https://doi.org/10.51298/vmj.v526i1A.5316
Issue
Vol. 526 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, V. T. . (2023). ANALYZING THE SURVIVAL OUTCOME AND TOXICITY OF INDUCTION CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER. Vietnam Medical Journal, 526(1A). https://doi.org/10.51298/vmj.v526i1A.5316

ANALYZING THE SURVIVAL OUTCOME AND TOXICITY OF INDUCTION CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER

Hùng Kiên Đỗ1,, Văn Tài Nguyễn1
1 k hospital

Main Article Content

Abstract

Objective: Analyzing survival outcome of induction TCF-regimen chemotherapy followed by concurrent chemoradiation in patients with locally advanced squamous cell head and neck cancer at K Hospital and assessing several toxicities of concurrent chemoradiation. Patients and method: Retrospective and prospective analysis of 47 patients with locally advanced squamous cell head and neck cancer who were treated with induction TCF-regimen chemotherapy followed by weekly platinum-based concurrent chemoradiotherapy at K Hospital from 01/2019 to 12/2022. Results: Median progression-free survival was 13.5 months. The 1-year and 2-year progression-free survival were 62%; and 29%, respectively. The common hematologic toxicity was neutropenia, often grades 1-2, and grades 3-4 neutropenia was observed in 4 patients. Grade 4 anemia was reported in 4.2% and grade 3 thrombocytopenia was seen in 2.1%. Non-hematologic toxicities were likely to be associated with radiotherapy, mostly grades 1-2. Grades 3 and 4 mucositis rates were 6.4% and 2.1%, respectively. Grades 3 and 4 xerostomia were observed in 4.2% and 2.1%, respectively. Conclusion: Induction TCF-regimen chemotherapy followed by concurrent chemoradiation for the treatment of locally advanced squamous cell head and neck cancer had improved progression-free survival with a controlable profile of toxicities.

Article Details

Keywords

squamous cell head and neck cancer, locally advanced, induction TCF-regimen chemotherapy

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71, 209–249, doi:10.3322/ caac.21660.
2. Nguyễn Văn Hiếu. Ung Thư Học; Nhà xuất bản Y học, 2015;
3. Schrijvers, D.; Van Herpen, C.; Kerger, J.; Joosens, E.; Van Laer, C.; Awada, A.; Van den Weyngaert, D.; Nguyen, H.; Le Bouder, C.; Castelijns, J.A.; et al. Docetaxel, Cisplatin and 5-Fluorouracil in Patients with Locally Advanced Unresectable Head and Neck Cancer: A Phase I-II Feasibility Study. Ann Oncol 2004, 15, 638–645, doi:10.1093/annonc/mdh145.
4. Colevas, A.D.; Norris, C.M.; Tishler, R.B.; Fried, M.P.; Gomolin, H.I.; Amrein, P.; Nixon, A.; Lamb, C.; Costello, R.; Barton, J.; et al. Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 1999, 17, 3503–3511, doi:10.1200/ JCO.1999.17.11.3503.
5. Colevas, A.D.; Norris, C.M.; Tishler, R.B.; Lamb, C.C.; Fried, M.P.; Goguen, L.A.; Gopal, H.V.; Costello, R.; Read, R.; Adak, S.; et al. Phase I/II Trial of Outpatient Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (OpTPFL) as Induction for Squamous Cell Carcinoma of the Head and Neck (SCCHN). Am J Clin Oncol 2002, 25, 153–159, doi:10.1097/00000421-200204000-00010.
6. Haddad, R.I.; Posner, M.; Hitt, R.; Cohen, E.E.W.; Schulten, J.; Lefebvre, J.-L.; Vermorken, J.B. Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Role, Controversy, and Future Directions. Ann Oncol 2018, 29, 1130–1140, doi:10.1093/annonc/mdy102.
7. Posner, M.R.; Glisson, B.; Frenette, G.; Al-Sarraf, M.; Colevas, A.D.; Norris, C.M.; Seroskie, J.D.; Shin, D.M.; Olivares, R.; Garay, C.A. Multicenter Phase I-II Trial of Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy for Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. J Clin Oncol 2001, 19, 1096–1104, doi:10.1200/ JCO.2001.19.4.1096.
8. Posner, M.R.; Hershock, D.M.; Blajman, C.R.; Mickiewicz, E.; Winquist, E.; Gorbounova, V.; Tjulandin, S.; Shin, D.M.; Cullen, K.; Ervin, T.J.; et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. N Engl J Med 2007, 357, 1705–1715, doi:10.1056/NEJMoa070956.
9. Vermorken, J.B.; Remenar, E.; van Herpen, C.; Gorlia, T.; Mesia, R.; Degardin, M.; Stewart, J.S.; Jelic, S.; Betka, J.; Preiss, J.H.; et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007, 357, 1695–1704, doi:10.1056/ NEJMoa071028.
10. National comprehensive Cancer network (NCCN) NCCN Practice Guideline for Head and Neck Cancer, Version 2022; 2022;